Modality
ADC
MOA
CFTRmod
Target
Cl18.2
Pathway
Ferroptosis
FTDCrohn's
Development Pipeline
Preclinical
Apr 2017
→ Oct 2030
PreclinicalCurrent
NCT06855541
1,174 pts·FTD
2022-05→2030-10·Recruiting
NCT05175286
1,338 pts·FTD
2017-04→2025-11·Completed
2,512 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-055mo agoInterim· FTD
2030-10-214.6y awayInterim· FTD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2025-11-05 · 5mo ago
FTD
Interim
2030-10-21 · 4.6y away
FTD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06855541 | Preclinical | FTD | Recruiting | 1174 | NT-proBNP |
| NCT05175286 | Preclinical | FTD | Completed | 1338 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |